Document Detail


Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.
MedLine Citation:
PMID:  23274926     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT(3) receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. METHODS: In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT(3) receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1. RESULTS: Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27 %, respectively. The efficacy was maintained in all cycles with over 80 % of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68 % episodes) than on days 1 to 3 (32 % episodes). Over any 24-h period, 49 % of patients with emesis reported no more than two episodes, and 62 % of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported. CONCLUSION: Adding 7 days of aprepitant to a 5HT(3) receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting.
Authors:
I N Olver; P Grimison; M Chatfield; M R Stockler; G C Toner; V Gebski; R Harrup; C Underhill; G Kichenadasse; N Singhal; I D Davis; A Boland; A McDonald; D Thomson;
Related Documents :
2913046 - Differences between ocular and generalized myasthenia gravis: binding characteristics o...
15022166 - Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cys...
1949606 - The therapeutic effects of 2,3-butanedione monoxime and atropine in severe dichlorvos i...
18375236 - Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
7085306 - Effect of patient size on doses received by patients in diagnostic radiology.
3572786 - Effects of n6-(l-phenylisopropyl)adenosine, caffeine, theophylline and rolipram on the ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-30
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  -     ISSN:  1433-7339     ISO Abbreviation:  Support Care Cancer     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Sydney Medical School, CEO Cancer Council Australia, GPO Box 408, Sydney, New South Wales, 2001, Australia, ian.olver@cancer.org.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluating a knowledge exchange intervention in cancer survivorship care: a workshop to foster imple...
Next Document:  Validation of the Chinese version of the Resilience Scale and its cutoff score for detecting low res...